A Phase 1/2 interventional study of ATL001 and Pembrolizumab in Advanced Non Small Cell Lung Cancer, sponsored by Achilles Therapeutics UK Limited. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by Achilles Therapeutics UK Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom — 102 open to participants now, 201 under way, 94 of them phase 3. Carcinoma, Non-Small-Cell Lung · United Kingdom.
Among the 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom, this one is the 482nd largest by enrollment of the 520 interventional ones that give a count, is one of 31 that started in 2019, is one of 70 in phase 1/2, and was the 331st registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →102 of the 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United Kingdom, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Argentina and 9 more countries
Ages 18+
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 15 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
568 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 172 · Phase 2 207 · Phase 3 210 · Phase 4 4
First in 1994; this study’s year is marked. 31 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 272 across the 520 interventional studies, 206 across the 37 observational. Of the 330 that completed or were terminated, 189 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
459 of 568 have an industry lead sponsor. The 10 most frequent:
Achilles Therapeutics UK Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.
Achilles Therapeutics UK Limited has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
40 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom that are under way reach primary completion within a year, 17 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05609968Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | 2027-01-12 |
| NCT05170204Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | 2027-01-19 |
Add all 40 to your calendar (.ics) → With an account.
Among the 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity of autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).
Patients will initially enter the study for procurement of tumour materials required to manufacture ATL001.
Following manufacture of ATL001, the product will be given back to eligible patients following lymphodepletion. Patients will continue to be followed up for a minimum of 5 years, as part of a separate Long Term Follow Up Protocol, or, if the separate protocol is not available at the study site, within this protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criteria will apply as per the protocol.
Exclusion Criteria:
Additional Exclusion Criteria will apply as per the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
Biological: ATL001
Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL- 2.
Biological: ATL001 · Drug: Pembrolizumab
Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
Biological: ATL001
ATL001 infusion
Checkpoint inhibitor
Assessment of Treatment Emergent Adverse Events (TEAEs) to Evaluate Safety and Tolerability
Evaluate TEAEs and serious AEs, by incidence, severity and relationship to ATL001
Time frame: 62 months due to early termination
Disease Assessment for Change From Baseline in Tumour Size
Evaluate the clinical activity of ATL001 in patients with advanced NSCLC using change from baseline in tumour size at week 6 , week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR)
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Disease Assessment for Time to Response (TTR) From ATL001 Infusion
Evaluate the endpoint of TTR by the investigator and ICR, per RECIST v1.1 and im-RECIST
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Disease Assessment for Objective Response Rate (ORR)
Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.
Time frame: Every 6 weeks for 6 months, then every 3 months (up to 62 months due to early termination)
Disease Assessment for Duration of Response (DoR). The DoR is Defined as the Time From the Date of First Documented Response Until the Date of Documented Disease Progression or Death
Evaluate the endpoint of DOR by the investigator and ICR, per RECIST v1.1 and im-RECIST
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Disease Assessment for Disease Control Rate (DCR)
Evaluate the endpoints of DCR as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Disease Assessment for Progression-Free Survival (PFS)
Evaluate the efficacy endpoints of PFS as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Overall Survival (OS)
Evaluate OS by the investigator
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
| Milestone | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Started | 22 | 0 | 5 |
| Completed | 0 | 0 | 0 |
| Not completed | 22 | 0 | 5 |
| Withdrew: Study termination by sponsor | 8 | 0 | 4 |
| Withdrew: Death | 12 | 0 | 0 |
| Withdrew: Progressive disease | 2 | 0 | 1 |
Evaluate TEAEs and serious AEs, by incidence, severity and relationship to ATL001
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| TEAEs | 21 | — | 5 |
| TEAEs related to any component of study treatment | 19 | — | 5 |
| Lymphodepletion related TEAEs | 16 | — | 4 |
| ATL001 related TEAEs | 16 | — | 4 |
| IL-2 related TEAEs | 16 | — | 5 |
| Serious TEAEs | 6 | — | 0 |
| Serious TEAEs related to any component of study treatment | 2 | — | 0 |
| Serious Lymphodepletion related TEAEs | 1 | — | 0 |
| Serious ATL001 related TEAEs | 1 | — | 0 |
| Serious IL-2 related TEAEs | 0 | — | 0 |
| TEAEs with CTCAE grade >= 3 | 16 | — | 5 |
| TEAEs with CTCAE grade >= 3 related to any component of study treatment | 14 | — | 4 |
| Lymphodepletion related TEAEs with CTCAE grade >= 3 | 12 | — | 4 |
| ATL001 related TEAEs with CTCAE grade >= 3 | 4 | — | 2 |
| IL-2 related TEAEs with CTCAE grade >= 3 | 6 | — | 3 |
| TEAEs leading to death | 0 | — | 0 |
| SAEs | 8 | 0 | 0 |
Evaluate the clinical activity of ATL001 in patients with advanced NSCLC using change from baseline in tumour size at week 6 , week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR)
Results for this outcome have not been posted.
Evaluate the endpoint of TTR by the investigator and ICR, per RECIST v1.1 and im-RECIST
Results for this outcome have not been posted.
Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Responders | 2 | 0 | 0 |
| Non-Responders | 20 | 0 | 5 |
Evaluate the endpoint of DOR by the investigator and ICR, per RECIST v1.1 and im-RECIST
Results for this outcome have not been posted.
Evaluate the endpoints of DCR as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST
Results for this outcome have not been posted.
Evaluate the efficacy endpoints of PFS as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST
Results for this outcome have not been posted.
Evaluate OS by the investigator
Results for this outcome have not been posted.
Collected over Each patient that received ATL001 would have been followed up for 24 months, to withdrawal of consent or death. Patients would then continue to be followed up for a minimum of 5 years as part of long term follow up. The study was terminated early due to sponsor decision. The Median follow-up period was 12 weeks (range: 3 - 48 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | 14/22 (63.6%) | 8/22 (36.4%) | 22/22 (100%) |
| Cohort C | 1/5 (20%) | 0/5 (0%) | 5/5 (100%) |
| Event | Cohort A | Cohort C |
|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/22 | 0/5 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/22 | 0/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/22 | 0/5 |
| Subcutaneous emphysemaSkin and subcutaneous tissue disorders | 1/22 | 0/5 |
| AscitesGastrointestinal disorders | 1/22 | 0/5 |
| TachypnoeaRespiratory, thoracic and mediastinal disorders | 1/22 | 0/5 |
| ConstipationGastrointestinal disorders | 1/22 | 0/5 |
| EncephalopathyNervous system disorders | 1/22 | 0/5 |
| VomitingGastrointestinal disorders | 1/22 | 0/5 |
| Confusional statePsychiatric disorders | 1/22 | 0/5 |
| Event | Cohort A | Cohort C |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 14/22 | 4/5 |
| Lymphocyte count decreasedInvestigations | 4/22 | 4/5 |
| Platelet count decreasedInvestigations | 0/22 | 4/5 |
| NauseaGastrointestinal disorders | 15/22 | 3/5 |
| Neutrophil count decreasedInvestigations | 5/22 | 3/5 |
| DiarrhoeaGastrointestinal disorders | 8/22 | 3/5 |
| RashSkin and subcutaneous tissue disorders | 3/22 | 3/5 |
| InsomniaPsychiatric disorders | 3/22 | 3/5 |
| PyrexiaGeneral disorders | 13/22 | 2/5 |
| FatigueGeneral disorders | 11/22 | 2/5 |
Cohort B never opened
| Age, Customized(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Age — <65 years | 19 | — | 1 | 20 |
| Age — >=65 years | 3 | — | 4 | 7 |
| Sex: Female, Male(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Female | 10 | — | 1 | 11 |
| Male | 12 | — | 4 | 16 |
| Race (NIH/OMB)(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | — | 0 | 0 |
| Asian | 1 | — | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | — | 0 | 0 |
| Black or African American | 0 | — | 0 | 0 |
| White | 18 | — | 4 | 22 |
| More than one race | 0 | — | 0 | 0 |
| Unknown or Not Reported | 3 | — | 0 | 3 |
| Region of Enrollment(participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| United States | 3 | — | 1 | 4 |
| United Kingdom | 11 | — | 1 | 12 |
| France | 3 | — | 0 | 3 |
| Germany | 4 | — | 2 | 6 |
| Spain | 1 | — | 1 | 2 |
| Body mass index (kg/m^2)((kg/m^2)) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Mean | 26.75 ± 5.818 | — | 27.10 ± 4.256 | 26.81 ± 5.490 |
| Baseline ECOG performance status(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Grade 0 | 8 | — | 2 | 10 |
| Grade 1 | 14 | — | 3 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Sep 2024, 62 months.
Results were first posted in Mar 2025, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Clonal Neoantigen T Cells ATL001
Carcinoma, Non-Small-Cell Lung →
Achilles Therapeutics UK Limited